Marvel Biosciences Corp. (MBCOF)
- Previous Close
0.0947 - Open
0.0947 - Bid --
- Ask --
- Day's Range
0.0947 - 0.0947 - 52 Week Range
0.0377 - 0.1400 - Volume
250 - Avg. Volume
1,810 - Market Cap (intraday)
4.224M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company is headquartered in Calgary, Canada.
marvelbiotechnology.comRecent News: MBCOF
Performance Overview: MBCOF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBCOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBCOF
Valuation Measures
Market Cap
4.21M
Enterprise Value
4.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-219.08%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.51M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
577.67k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-225.83k
Company Insights: MBCOF
MBCOF does not have Company Insights